Jens Huober Selected Research

Epirubicin (Ellence)

1/2022	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
12/2020	Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial.
1/2019	NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
1/2019	Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial.
1/2018	Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
2/2017	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
6/2016	Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial.
10/2015	A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
7/2015	Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
7/2013	Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jens Huober Research Topics

Disease

135	Breast Neoplasms (Breast Cancer) 08/2022 - 01/2002
65	Neoplasms (Cancer) 01/2022 - 01/2002
19	Pathologic Complete Response 01/2022 - 12/2004
9	Triple Negative Breast Neoplasms 01/2022 - 06/2014
7	Diarrhea 01/2021 - 12/2004
7	Ovarian Neoplasms (Ovarian Cancer) 11/2015 - 12/2006
5	Neoplasm Metastasis (Metastasis) 10/2021 - 01/2012
5	Circulating Neoplastic Cells 11/2019 - 05/2010
4	Neutropenia 01/2021 - 07/2013
4	Ovarian Epithelial Carcinoma 08/2012 - 12/2006
3	Disease Progression 11/2021 - 01/2011
3	Carcinoma (Carcinomatosis) 10/2017 - 03/2004
3	Infections 07/2015 - 01/2012
3	Exanthema (Rash) 07/2013 - 04/2007
3	Febrile Neutropenia 01/2012 - 12/2004
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2021 - 01/2010
2	Fatigue 12/2020 - 06/2016
2	Leukopenia 12/2020 - 11/2017
2	Anemia 12/2020 - 01/2006
2	Cardiotoxicity 04/2018 - 04/2010
2	Vomiting 06/2016 - 04/2007
2	Thrombocytopenia (Thrombopenia) 06/2014 - 07/2013
2	Residual Neoplasm 10/2013 - 12/2006
2	Hand-Foot Syndrome 01/2012 - 04/2010
2	Inflammatory Breast Neoplasms 12/2011 - 01/2010
1	Convalescence 01/2022
1	Arthralgia (Joint Pain) 08/2021
1	Pain (Aches) 08/2021
1	Pneumonia (Pneumonitis) 01/2021

Drug/Important Bio-Agent (IBA)

35	Hormones (Hormone)IBA 08/2022 - 04/2008
29	Trastuzumab (Herceptin)FDA Link 07/2022 - 06/2006
22	taxaneIBA 01/2021 - 04/2007
21	AnthracyclinesIBA 01/2021 - 04/2007
20	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 04/2008
19	human ERBB2 proteinIBA 07/2022 - 01/2009
19	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2006
18	Epirubicin (Ellence)FDA LinkGeneric 01/2022 - 12/2004
12	Docetaxel (Taxotere)FDA Link 12/2020 - 12/2004
11	ErbB Receptors (EGF Receptor)IBA 08/2022 - 04/2010
11	Lapatinib (GW572016)FDA Link 10/2021 - 04/2008
10	Bevacizumab (Avastin)FDA Link 01/2020 - 04/2008
10	Phenobarbital (Luminal)FDA Link 10/2019 - 11/2010
9	Biomarkers (Surrogate Marker)IBA 07/2022 - 12/2004
8	abemaciclibIBA 08/2022 - 11/2017
8	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 09/2010
8	Capecitabine (Xeloda)FDA Link 10/2015 - 04/2008
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 04/2008
5	liposomal doxorubicin (Doxil)FDA Link 01/2022 - 01/2010
5	Messenger RNA (mRNA)IBA 01/2022 - 02/2013
5	Aromatase InhibitorsIBA 06/2021 - 12/2004
5	PlatinumIBA 06/2014 - 04/2007
4	Tamoxifen FDA LinkGeneric 08/2022 - 04/2007
4	Estrogen ReceptorsIBA 11/2021 - 11/2014
4	Pharmaceutical PreparationsIBA 02/2021 - 04/2007
4	Fluorouracil (Carac)FDA LinkGeneric 12/2020 - 10/2015
3	130-nm albumin-bound paclitaxelIBA 01/2022 - 10/2015
3	Ado-Trastuzumab EmtansineIBA 01/2022 - 01/2016
3	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2019
3	pertuzumabIBA 01/2022 - 07/2015
3	Proteins (Proteins, Gene)FDA Link 11/2021 - 01/2016
3	Diphosphonates (Bisphosphonates)IBA 08/2021 - 10/2013
3	Progesterone Receptors (Progesterone Receptor)IBA 06/2021 - 11/2014
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 04/2020 - 06/2011
3	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 10/2017
3	ParaffinIBA 01/2020 - 10/2014
3	Biological ProductsIBA 01/2020 - 12/2004
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2015 - 04/2008
3	Gemcitabine FDA Link 09/2010 - 12/2004
2	Zoledronic Acid (Zometa)FDA Link 08/2021 - 10/2013
2	Fulvestrant (Faslodex)FDA Link 01/2021 - 11/2017
2	AntidiarrhealsIBA 01/2021 - 01/2021
2	Cyclin-Dependent Kinase 4IBA 01/2021 - 11/2017
2	Epoetin Alfa (Epogen)FDA Link 12/2020 - 07/2013
2	Immune Checkpoint InhibitorsIBA 04/2020 - 01/2020
2	Formaldehyde (Formol)FDA Link 01/2018 - 10/2014
2	Everolimus FDA Link 02/2016 - 07/2013
2	lonafarnib (SCH 66336)IBA 11/2015 - 08/2012
2	Vinorelbine (Navelbine)FDA LinkGeneric 08/2013 - 04/2008
1	LigandsIBA 01/2022
1	CalciumIBA 01/2022
1	Denosumab FDA Link 01/2022
1	atezolizumabIBA 01/2022
1	Complement System Proteins (Complement)IBA 12/2021
1	AlpelisibIBA 11/2021
1	LSZ102IBA 11/2021
1	ribociclibIBA 11/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021

Therapy/Procedure

54	Therapeutics 08/2022 - 12/2004
54	Neoadjuvant Therapy 01/2022 - 12/2004
44	Drug Therapy (Chemotherapy) 01/2022 - 12/2004
7	Adjuvant Chemotherapy 08/2021 - 06/2010
6	Aftercare (After-Treatment) 01/2020 - 01/2010
3	Drug Tapering 01/2021 - 04/2007
3	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 01/2009
3	Segmental Mastectomy (Lumpectomy) 11/2018 - 12/2004
2	Resistance Training 01/2022 - 06/2018
2	Immunotherapy 01/2022 - 12/2019
1	Radiotherapy 10/2021
1	Operative Surgical Procedures 10/2021
1	Duration of Therapy 08/2021